Roche reported a 7% sales growth in Q3 at constant currency, driven partly by early shipments in Japan. Pharmaceuticals performed well, but Chinese pricing reforms negatively impacted its Diagnostics segment. Foreign exchange fluctuations also weighed on reported earnings. Future growth may come from drugs like giredestrant and fenebrutinib, though regulatory approvals and market success remain uncertain. Despite a 10% share price rise since a downgrade, earnings estimates and guidance remain stable, leading to a maintained Neutral rating with a 17.5x P/E valuation.
Roche's valuation and recent performance provide context for health sector activity on Pluang as of Oct 29, 2026 00:22 WIB. Among 150 priced US health stocks, 100 advanced and 49 declined today. Notable movers include CTXR at USD 0.54 with a 5.55% gain and balanced buy/sell orders, RGEN at USD 185.43 up 5.48%, and WGS at USD 66.03 rising 5.24% with predominantly buy orders. The most notable figure is the 100 stocks that rose in the sector.
SpaceX reported a strong Q3 with revenue up 161% year-over-year to $14.6 billion and a net profit of $4.4 billion, reversing last year's loss. Starlink, its satellite internet service, grew revenue by nearly 70% to $5.2 billion and added 1.6 million ...
SPIE, a leading European multi-technical services provider, has signed an agreement to acquire a 76% stake in SAR ANLAGENBAU GmbH, a major electrical engineering and automation firm based in Austria and Germany. This acquisition will enhance SPIE's p...
SPIE, a European leader in energy and communication services, has agreed to acquire a 76% stake in SAR ANLAGENBAU GmbH, a key electrical engineering and automation firm in Austria and Germany. This acquisition will broaden SPIE's service portfolio in...
The global dermatological therapeutics market is projected to grow from about $43 billion in 2025 to $97 billion by 2034, with a compound annual growth rate of around 10%. This growth is fueled by increasing cases of acne, psoriasis, and other chroni...
Blockchain.com has launched TRX options trading, providing easier access to TRON's native token through its platform. This move expands the TRON ecosystem's reach by simplifying options trading for retail and institutional users worldwide. TRON, know...
